The Aethlon Hemopurifier

Aethlon Hemopurifier

The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.

As of March 2023, we are currently conducting a clinical trial in Sars-COV2 at the Medanta Metacity Hospital in India and are in the process of launching a clinical trial in oncology in Australia.

Information from previous clinical trials in the United States can be accessed below.